A Chicken & Waffles Breakfast Sandwich and a Chicken & Waffles Sandwich will hit certain restaurants in Baltimore from Dec. 1 through Jan. 24, while supplies last. In San Antonio, certain restaurants will test the Chicken & Waffles Breakfast Sandwich through January while supplies last, Chick-fil-A told FOX Business.

The sandwiches were described as “crispy chicken stacked between warm maple waffles, all with a touch of smoked bacon.”

The limited menu offering is a way for companies to test out certain products. If the feedback, operations and economics are favorable, the company could decide to launch it nationwide. 

Competition in the fast-food sector has become tougher in the current economic climate. Brands are looking to attract customers as rising menu prices have forced many people to cut back on dining out. Lower-income consumers, who make up a large share of the industry’s customer base, have been hit the hardest, adding pressure on chains to find new ways to stand out.

A Chicken & Waffles Breakfast Sandwich and a Chicken & Waffles Sandwich will hit certain restaurants in December. Chick-Fil-A

The limited menu offering is a way for companies to test out certain products. Christopher Sadowski

Rival KFC is trying to rejuvenate itself by leaning into its own version of the chicken sandwich, an item that’s stoked competition among major chains, Other new innovations on KFC’s menus, such as spicy wings and potato wedges, have proven popular among customers.

The company also launched a one-day-only pop-up restaurant in New York City on Nov. 9 called “Sundays,” where customers were able to order the company’s version of its classic chicken sandwich. 

It was a jab at Chick-fil-A, which is closed on Sundays. 

Some brands, such as McDonald’s and IHOP, are leaning on value meals, while others are focusing on menu innovations to drive traffic.

The post Chick-fil-A testing new sandwiches in 2 cities for a limited time appeared first on Our Story Insight.

Waksal, who is not a medical doctor, imported the veterinary drug along with other “unapproved ingredients” from Colombia to treat a “severely ill” child whose mother worked for the company, according to the complaint filed this week in federal court in Manhattan.

Waksal allegedly monitored the child’s response to the drug in an effort to develop a similar product for his former company, Equilibre Biopharmaceuticals, the lawsuit alleged.

Sam Waksal, 77, has founded a number of biotech firms. Youtube/CNBC

The alleged dosing took place over “a several month period” and came to light when an Equilibre whistleblower exposed the scheme in 2022, Neal Brickman, an attorney representing Equilibre, told The Post.

The child’s health status is not known, according to Brickman.

The whistleblower, who was an employee at the time, also accused Waksal of sexual harassment and of creating a hostile work environment, according to the complaint – though the lawsuit does not provide details.

Waksal, now 77, famously sold off his ImClone shares in 2001 after he learned that the FDA would not approve the company’s cancer drug. He served five years in prison for securities fraud while Stewart served five months for lying about why she sold her ImClone shares before they tanked.

Sam Waksal, center, in 2002. He famously sold off his ImClone shares in 2001 after he learned that the FDA would not approve the company’s cancer drug AP

Waksal declined to comment when reached this week, but he provided The Post with screenshots of text exchanges that he claimed were between himself and the mother of the child in 2022 after she learned about the investigation. 

“I hope they understand that we’re dealing with a dying child and you were being kind and compassionate,” the mother allegedly wrote. “I fully understood the risks.”

The Post was not able to independently confirm that the texts, which appeared to span a period from May 2022 to December 2022, were from the mother.

Martha Stewart waving to fans outside federal court in 2003. She served five months for lying about why she sold her ImClone shares before they tanked. The New York Post

“Sam knew the drug was not approved [by the FDA] for use by a human but he did it anyway,” Brickman said. “He brought the drug into the country illegally by improper means and he administered it knowing he shouldn’t do that.”

“He stopped treating the child when the company found out that he was doing this — not because the child got sick or better from the dosing,” Brickman added.

Waksal is also accused of impeding the investigation by placing the mother on administrative leave from her job at Equilibre to prevent her from talking to the investigators, according to the complaint.

Waksal “illegally” imported a veterinarian drug from Colombia to administer to a child in the US who suffers from epilepsy. Shutter2U – stock.adobe.com

Another witness was also offered $100,000 of company funds to influence her participation in the investigation, according to the complaint.

The allegations sparked an investigation conducted by two outside law firms, which resulted in Waksal’s forced resignation in 2022 as chairman and chief executive of Equilibre, which he had founded just two years earlier, according to the complaint.

Equilbre informed the FDA about the incident, according to the complaint.

“There was no official reprimand as far as we are aware of,” Brickman said.

Waksal’s firm Graviton was named as a defendant in the lawsuit.

This lawsuit names Waksal, three Equilibre directors and another biotech firm Waksal owns – Graviton – as defendants, accusing them of “reckless disregard for legal, ethical and corporate governance standards.”

The board members, including one who gave the drug concoction to his ill dog who died the next day, are described as complicit in the scheme, according to the filing.

After Waksal was removed from Equilibre, he began to “sabotage” the company, according to the complaint, steering investors to Graviton and “converting” Equilibre’s research, intellectual property and other assets to Graviton.

The lawsuit alleges Waksal steered investors to Graviton and “converting” Equilibre’s research, intellectual property and other assets to Graviton (headquarters above). Google Maps

Equilibre filed for bankruptcy protection in 2023 and a US trustee who represents the company’s creditors filed the complaint, which is seeking at least $150 million.

A spokesperson for Graviton issued a statement: “Graviton Bioscience is performing innovative, genuinely ground-breaking scientific work in multiple disease areas that could, in the near-term, dramatically improve the lives of patients suffering from cancer, Lou Gehrig’s Disease, Alzheimer’s, autoimmune disorders, and multiple other indications.

“With such robust prospects, it is perhaps no surprise that Graviton is a target. The Company is aware of the filings, which we know to be without merit, and will launch a vigorous defense.”  

Graviton received an undisclosed investment last year from Sanofi, which acquired another company Waksal founded – Kadmon – for $2 billion in 2021.

The post Biotech mogul Sam Waksal of Martha Stewart fame accused of testing illegal ‘swine drug’ on child appeared first on Our Story Insight.